- Stock: In Stock
- Brand: Incepta Pharmaceuticals
- Product ID: Filgrastim
100% Secure Payment
Filgrastim (G-CSF) 30 million units (30 MU) or 300mcg in pre-filled syringe containing 0.5ml concentrated solution for subcutaneous or intra¬venous injection or infusion.
Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology.
Dosage & admin: See above under the text.
30 MIU (0.5ml) amp x l's pack: 2890.00 MRP
Description
Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology. G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation, differentiation and enhances phagocytic activity.
Indications
Cancer patients receiving myelosuppressive chemotherapy
Patients with Acute Myeloid Leukemia receiving induction or consolidation chemotherapy
Cancer patients receiving bone marrow transplant
Patients with severe neutropenia
Peripheral blood progenitor cell collection and therapy
Dosage & Administration
Cancer patients receiving myelosuppressive chemotherapy: The recommended starting dose of Filgrastim is 5 mcg/kg/day. Doses may be increased in increments of 5 mcg/kg for each chemotherapy cycle
Cancer patients receiving bone marrow transplant: The recommended dose of Filgrastim following bone marrow transplantation is 10 mcg/kg/day. During the period of neutrophil recovery, the daily dose should be titrated against the neutrophil response as follows:
Absolute Neutrophil Count (ANC) Dose adjustment
ANC>1000/mm3 for consecutive 3 days Reduces to 5 mcg/kg/day
Then, If ANC remains >1000/mm3 for consecutive 3 days Discontinue drug
Then, If ANC remains <1000/mm3 for consecutive 3 days Resume at 5 mcg/kg/day
Patients with chronic neutropenia: The recommended daily starting dose is 5 mcg/kg/day in idiopathic neutropenia
Peripheral blood progenitor cell collection and therapy: The recommended starting dose is 10 mcg/kg/day. Dose may be adjusted as required
Side Effects
• Splenic rupture
• Acute Respiratory Distress Syndrome
• Alveolar hemorrhage and haemoptysis
• Sickle cell crisis
Precautions
• Filgrastim should not be administered within 24 hours before and after chemotherapy
• The possibility of Filgrastim acting as a growth factor for any tumor type cannot be excluded
• To avoid adverse effects of excessive neutrophils complete blood count is recommended twice per week during treatment
• Filgrastim is given by subcutaneous or intravenous infusion as required
• Dilution of Filgrastim conc less than 5 mcg/ml is not recommended at any time
• Filgrastim may be diluted in 5% dextrose as required
Use in Pregnancy & Lactation
There are no adequate and well controlled trial on pregnant women, the effect of Filgrastim on the developing fetus and mother is unknown.
Drug Interaction
Drug interactions between Filgrastim and other drugs have not been fully evaluated. Drugs which may potentiate the release of neutrophils, such as lithium should be used with caution.
Over Dose
The possibility of Filgrastim acting as a growth factor for any tumor type and adverse effects of excessive neutrophils may occur in overdose of Filgrastim.
Storage
Filgrastim should be stored at 2°C to 8°C in a refrigerator and shaking should be avoided.
